The US-based Forest Laboratories has entered into a settlement agreement with Glenmark Generics Inc USA, in a patent infringement litigation at the US court.
Forest had filed suit against Glenmark, which sought approval with USFDA to market generic versions of Forest's hypertension drug - Bystolic (nebivolol) tablets.
Under the terms of the settlement agreement, Forest will provide a licence to Glenmark that will permit it to launch its generic versions of Bystolic by three months prior to the expiration of US Patent or the date Glenmark receives final FDA approval of its ANDA.
Forest had settled similar patent infringement suits with Indian companies such as Hetero Labs, Alkem Laboratories, Indchemie Health Specialties and Torrent Pharmaceuticals. Bystolic, a once-daily treatment for the treatment of high blood pressure, was introduced in the US in 2008.
